Advanced searches left 3/3

Carcinoma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 04 December 2022

* If you want to update the article please login/register

Ablation of Hepatocellular Carcinoma: a Nationwide Study

The connection between recovery after ablation and HCC tumor size will be investigated first. The result after ablation in patients with HCC-related to HCV will be investigated in patients with HCC related to HCV in the second year will be investigated. HCV causes in patients with HCC are different from those with HCV primarily because of other reasons than HCV. Purpose is a big cohort of patients with HCC treated with ablation therapy. With findings from the Danish Liver and Bile Duct Cancer Database, the Danish Database for Hepatitis B and C, and the National hepatitis laboratory database, a large cohort of patients with ablation therapy will be investigated for the following objectives: Investigate correlations between HCC tumor size and survival after ablation therapy, the following aims are investigated. Hypotheses: In patients with large HCC tumors and those with small tumors, survival after ablation therapy is lower than in patients with small tumors. Patients with HCV are more likely to die after ablation than in patients with HCC due to HCV rather than in patients with HCC due to other causes. Patients with HCV infection can be identified with HCV-infected patients versus patients without HCV infection, according to data from the DANHEP and DANVIR databases, and studies on the effects of ablation in HCV-infected patients with HCV can be determined. In both univariable and multivariable studies, Cox proportional hazard regression model will be used to determine risk factors that influence prognosis and survival following ablation. Perspectives of a large group of patients With evidence from national databases, the aim is to determine survival outcomes for HCC and the causes of tumor size and etiology of HCC.

Source link: https://clinicaltrials.gov/ct2/show/NCT05498779


18F-DCFPyL PET/CT in Hepatocellular Carcinoma

PSMA has been found not only on prostate cancer cells, but also on cell lines of other malignancies, as well as tumor endothelium. PSMA in the tumor vasculature, according to a recent study. Early and during the process of hepatic tumorigenesis, endothelial cell transplantation to HCC is likely, resulting in the development of HCC, making an endothelial cell tracer an effective marker to detect early disease. Unlikely PSMA antibody binds the second generation PSMA PET agent, 18F-DCFPyL, a second generation PSMA PET agent, binds with high affinity to PSMA but this agent's whole body PET imaging with this agent can help with diagnosis of high risk cancers and detecting recurrent disease. Participants > = 18 years old: Objective: To determine sites of hepatocellular carcinoma with at least one measurable lesion on standard imaging modality. Eastern Cooperative Oncology Group is a multi-site imaging research project involving participants with suspected hepatocellular carcinoma. Within about 2 weeks of the 18F-DCFPyL PET/CT images, participants will be again scanned with an 18F-FDG PET/CT imaging. During the first routine follow-up period, typically within 4-8 weeks, participants with a baseline positive 18F-DCFPyL-PET/CT imaging and biopsy confirming HCC diagnosis will undergo a post-treatment 18F-DCFPyL-PET/CT imaging and biopsy confirm HCC diagnosis will be offered a post-treatment 18F-DCFPyL-PET/CT imaging and biopsy confirming HCC diagnosis will undergo a post-treatment 18F-DCFPyL PET/CT image and biopsy a et period, 4-6 weeks, participants with a baseline positive 18F-treatment 18F-W-PET/CT imaging and biopsy confirming HCC diagnosis will performa HCC diagnosis, a HCC diagnosis. A positive HCC biopsy will be followed for five years to determine progression free survival.

Source link: https://clinicaltrials.gov/ct2/show/NCT05009979


Harms of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis

This research seeks to: Aim 1: Assess the effect of hepatocellular carcinoma screening in a socioeconomically and racially diverse group of patients with cirrhosis followed in three healthcare settings over a 4-year period, including electronic medical record analysis, manual chart review, and validated survey methods. Aim 3: Create and disseminate a balance sheet of benefits and risks to inform patients, doctors, healthcare companies, payers, and policy makers about the benefits of hepatiocellular carcinoma screening in patients with cirrhosis. Electronic medical record data collected over a four-year period will be used to compare screening-related physical and financial risks among patients undergoing and those not underwent hepatocellular carcinoma screening.

Source link: https://clinicaltrials.gov/ct2/show/NCT03756051


A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma

After liver SBRT, it was determined by radiographic local response, local monitoring, and time to local progression of treated lesions in HCC patients. In HCC patients treated with liver SBRT, there is no way to determine overall survival and cancer-specific survival. To determine the extent of persistent tumor and the extent of radiation damage within and around the irradiated field, an explanted irradiated liver tissue biopsy was used to determine the presence of a residual tumor and the degree of radiation exposure within and outside the irradiated field.

Source link: https://clinicaltrials.gov/ct2/show/NCT01899261


Prevalence and Prognostic Impact of Epigenetic MMRd in Endometrial Carcinomas

Many with MMR abnormalities associated with epigenetic MMR deficiency were classified as potential MMR mutations by IHC and MLH1 methylation, while others without MLH1 methylation were classified as likely MMR mutations, and those without MMRd were classified as probable MMR mutations, and those without MMRd were classified as MMR-competent, while others without methylation were classified as possible MMR mutations, and those without MMR methylation were classified as epigenetic MMR abnormalities by IHC and methylation were classified as epigenetic MMR mutations, MMR mutations as epigenetic MMR methylation were labele MMR methylation were classified as suspected as potential MMR mutations as MMR methylation were classified as MMR methylation were classified as MMR methylation were classified as MMR methylation were classified as MMR methylation as MMR methylation were classified as MMR-MMR-MMR-MMR-MMR-MMR-MMR-MMR-MMR-MMR-MMR- The epigenetic MMRd prevalence in endometrial cancer is the first study, and the Lynch/ Lynch-like population differs between the epigenetic MMRd population, MMRd-tolerant population, and the Lynch/ Lynch-like population.

Source link: https://clinicaltrials.gov/ct2/show/NCT05334303


Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma

To determine the safety/tolerability of pembrolizumab in unresectable patients with thymoma or thymic carcinoma who do not have pre-existing autoimmune disorders. To determine the anti-tumor activity of pembrolizumab in patients with unresectable thymoma or thymic carcinoma. To determine whether pedigolizumab's progression-free survival and overall survival in patients with unresectable thymoma or thymic carcinoma will be determined. We'll use archival or new tumor tissue for PD-L1 immunohistochemistry. Pesolizumab's clinical study will be done by Guardant360 blood testing on patients with thymoma and thymic carcinoma to see if any specific genetic mutations related to toxicities or clinical outcomes.

Source link: https://clinicaltrials.gov/ct2/show/NCT03295227


MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma

The change in MDSC level from diagnosis to after nephrectomy is seen in patients with suspected localized renal cell carcinoma who undergo nephrectomy. Determine the change in MDSC level from baseline to after treatment in patients with a confirmed metastatic renal cell carcinoma who receive systemic therapy, and, secondarily, to compare these changes to tumor burden changes as determined by computed tomography scan or other imaging technique. Patients with localized renal cell carcinoma are eligible for blood and urine samples at baseline and post nephrectomy for analysis by the Flow Cytometry MDSC Clinical Assay. Patients with metastatic renal cell carcinoma are first identified at baseline and then followed by four months of systemic therapy for analysis by the Flow Cytometry MDSC Clinical Assay.

Source link: https://clinicaltrials.gov/ct2/show/NCT02664883


A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

Only patients with histological confirmation of FIGO Stage III/IV epithelial adenocarcinoma of ovarian, tubal, or peritoneal origin will be assessed and admitted to the study. In the Genomic Core Facility at UConn Health, the surgically cut tumor as well as standard cells from peripheral blood will be used to obtain RNA and DNA sequencing of the tumor and normal transcriptomes, as well as normal exome sequencing. The patient's blood cells will also be HLA coded. This research seeks to develop and test the effectiveness of a new experimental vaccine named OncoImmunome in people with Stage III/IV Ovarian Cancer. The United States Food and Drug Administration's "experimental vaccine" is a vaccine that is being tested and is not approved for sale in the United States by the U. S. Food and Drug Administration, and it is not approved for use in the United States by the U. S. Food and Drug Administration. The following information will be published: Tumor Tissue and Blood Sample Collection: The intention of this portion of the study is to gather participant's blood and tumor tissue and analyze it for genetic mutations. These test findings will be used to develop a study vaccine that is unique to the participant and their ovarian cancer. The study will be published over a six-month course, and six months patients will receive the study vaccine 1 study vaccine dose per month or six study vaccine doses total. However, the researchers will continue to gather all subjects data for up to five years from the time they released their tumor sample and blood for the study.

Source link: https://clinicaltrials.gov/ct2/show/NCT02933073


Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

History: Pancreatic Acinar Cell Carcinoma is a rare pancreatic tumor that accounts for around 0. 5 percent of all pancreatic malignancies. Mutations in DNA repair genes have been shown in ovarian and prostate cancer patients' blood samples to identify subgroups of cancer patients with specific vulnerability to DNA damage response inhibitors, as shown by gene mutations in DNA repair genes. With olaparib, PACC will be sensitive to PARP inhibition, as PACC has several signs of HRR deficiency. Participants with platinum-resistant pancreatic cell carcinoma must have advanced previously treated PACC; not have platinum-resistant disease. Objective: To determine the anti-tumor activity of single agent olaparib, a PARP inhibitor, in patients with platinum-sensitive advanced pancreatic acinar cell carcinoma, participants must have advanced previously treated PACC Participants must not have platinum-resistant disease Age >=18 years.

Source link: https://clinicaltrials.gov/ct2/show/NCT05286827

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions